AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8955577
Drug: Magic Lite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magic Lite (ML)
Trial: 25336068
Drug: Hatha yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hatha yoga intervention (12-week, twice-weekly)
Trial: 16542201
Drug: Tezosentan (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (2.5, 5.0, 12.5 and 25 mg h(‐1))
Trial: 9489813
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) treatment for RA
Trial: 7836695
Drug: D-propoxyphene (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-propoxyphene (0.7 mg/kg body weight)
Trial: 3402341
Drug: Routine weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Routine weekly catheter replacement
Trial: 29659956
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice polyphenols (GJPs) 300 mg/d for 1 month
Trial: 26053138
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of galactose/day followed by 500 mg for 2 weeks
Trial: 23641006
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) ON
Trial: 19051551
Drug: Oral B‐‐alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B‐‐alcohol free
Trial: 19051551
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide bleaching agent (Vivastyle)
Trial: 16815189
Drug: Inhaled morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled morphine (65 mug kg(‐1) morphine sulphate, 3 mL via oral nebulizer)
Trial: 16815189
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (physiological saline, 3 mL via oral nebulizer)
Trial: 16815189
Drug: Inhaled morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled morphine
Trial: 15124547
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy in stage IIb and higher seminoma
Trial: 10882586
Drug: Protease inhibitor-containing
RxNorm normalized name: Protease inhibitor-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-containing regimen
Trial: 7565327
Drug: Symptomatic therapies,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapies, ampicillin, co‐trimoxazole
Trial: 20492840
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg/d)
Trial: 17012455
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate 20 mg, administered three times per day for 1 week, then 20 mg per day for the next 3 weeks
Trial: 17012455
Drug: Monophasic combination
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic combination oral contraceptive (OC) containing 1 mg norethindrone and 35 mcg of ethinyl estradiol, administered three times per day for 1 week, then one tablet per day for the next 3 weeks
Trial: 15040791
Drug: Patient information
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient information booklet about menorrhagia and treatment options, mailed before the first visit to the outpatient clinic.
Trial: 10740328
Drug: Oral trimegestone
RxNorm normalized name: promegestone
DrugBank: Promegestone (DB13602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day)
Trial: 1280464
Drug: Additional radiotherapy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional radiotherapy after chemotherapy
Trial: 1280464
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment or additional chemotherapy
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in normal renal function
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in mild renal impairment
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in moderate renal impairment
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in severe renal impairment
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in ESRD without hemodialysis
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in ESRD with hemodialysis
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol in ESRD with and without hemodialysis
Trial: 30865315
Drug: 75-mg single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg single-dose solriamfetol during hemodialysis
Trial: 30865315
Drug: Study drug-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug-related adverse events
Trial: 30583748
Drug: Circulating bio‐ADM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating bio‐ADM levels upon admission > 70 pg/ml
Trial: 26992115
Drug: Bioabsorbable steroid-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable steroid-eluting sinus implant (mometasone furoate)
Trial: 25262257
Drug: Single-antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-antiplatelet therapy (SAPT)
Trial: 17436202
Drug: Echinacea supplement
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea supplement for 4 weeks
Trial: 16214443
Drug: Pravastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin treatment for 6 months
Trial: 12001761
Drug: Valproate or
RxNorm normalized name: valproate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate or carbamazepine in monotherapy or combination of phenobarbital and phenytoin and the combination of phenobarbital, phenytoin and primidone in polytherapy
Trial: 10544903
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) given as an intravenous bolus of 80 U/kg followed by a constant infusion of 18 U/kg/h
Trial: 10544903
Drug: Nadroparin 185
RxNorm normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 185 AXa IU/kg once daily subcutaneously
Trial: 7792126
Drug: Amoxicillin-clavulanate (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (amoxicillin 40 mg/kg/day 3 times a day)
Trial: 1977256
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream applied for 30, 60, 90, and 120 min on various body locations.
Trial: 1977256
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream on the back.
Trial: 1977256
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream in the cubital fossa and on the hand.
Trial: 25533243
Drug: 5Hz‐rTMS (treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5Hz‐rTMS (treatment)
Trial: 19494551
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests for orientation, memory, attention, executive function, and abstraction and judgment
Trial: 19494551
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests for memory, attention, executive function, and abstraction and judgment (excluding orientation)
Trial: 16423089
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg q.d., esomeprazole 20 mg b.i.d., and amoxicillin 1 g b.i.d.
Trial: 16423089
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.
Trial: 15598479
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg tablet
Trial: 15598479
Drug: Gefitinib dispersion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib dispersion preparation via drink
Trial: 15598479
Drug: Gefitinib dispersion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib dispersion preparation via nasogastric tube
Trial: 11306524
Drug: CEE+MP (micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+MP (micronized progesterone 200 mg)
Trial: 11306524
Drug: CEE+MPA (medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+MPA (medroxyprogesterone acetate 10 mg)
Trial: 9403262
Drug: Stoxil topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stoxil topical ointment
Trial: 29032139
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg twice daily (50 mg once daily if treated with a sulfonylurea)
Trial: 20156151
Drug: Intraperitoneal drug
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal drug therapy (IP chemotherapy)
Trial: 20156151
Drug: Intraperitoneal drug
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal drug therapy
Trial: 9364183
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone 1000 micrograms twice daily for three months
Trial: 9364183
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 30 mg/day for ten days after each treatment phase
Trial: 2419692
Drug: Pinacidil 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil 37.5 mg
Trial: 2419692
Drug: Pinacidil 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil 37.5 mg + Propranolol 40 mg
Trial: 20394495
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelaic acid 5% and erythromycin 2% gel (AzE)
Trial: 18661887
Drug: High-protein, high-caloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein, high-caloric supplement (3 daily servings)
Trial: 11803323
Drug: Dopamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (2 mg/kg x min)
Trial: 22211362
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of cloprostenol (87.5 μg; 1.0 ml; i.m.)
Trial: 22211362
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of cloprostenol (43.75 μg; 0.5 ml)
Trial: 22211362
Drug: One third
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One third dose of cloprostenol (26.25 μg; 0.3 ml)
Trial: 19205289
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 800 microg/d during pollen season
Trial: 11605103
Drug: High soya
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High soya diet (100 mg total isoflavones/day)
Trial: 11605103
Drug: Low soya
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low soya diet (0.5 mg total isoflavones/day)
Trial: 9623031
Drug: Risperidone, final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone, final dose 6 mg
Trial: 8076566
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine gel applied to the throat for 20 minutes
Trial: 8076566
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine solution administered by gargling for five minutes
Trial: 1091183
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of haloperidol
Trial: 31843007
Drug: Delayed RRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed RRT strategy (RRT initiated only if a potentially severe condition occurs or serum urea concentration reaches 50 mmol/l)
Trial: 26611718
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day omega-3 fatty acid from flaxseed oil
Trial: 23948819
Drug: NWB bi-weekly
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NWB bi-weekly group exercise class
Trial: 19336785
Drug: Routine psychosocial
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine psychosocial care and selective serotonin reuptake inhibitors (SSRIs)
Trial: 19336785
Drug: Routine psychosocial
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine psychosocial care, selective serotonin reuptake inhibitors (SSRIs), and cognitive-behavioural therapy (CBT)
Trial: 11775133
Drug: COER-verapamil (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER-verapamil (180 to 540 mg/day)
Trial: 7986516
Drug: Subcutaneous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous verapamil
Trial: 25652104
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg nebulized magnesium
Trial: 19080649
Drug: Firebird DES
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firebird DES implantation and Tirofiban intravenous injection (10 microg x kg(‐1) within 3 minutes followed by 0.15 microg x kg(‐1) x min(‐1) for 36 hours)
Trial: 2208024
Drug: Intraarterial cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial cisplatin (DDP) with systemic doxorubicin, high-dose methotrexate, and ifosfamide
Trial: 2208024
Drug: Intravenous cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin (DDP) with systemic doxorubicin, high-dose methotrexate, and ifosfamide
Trial: 38180
Drug: Treatment (specifics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (specifics not provided)
Trial: 31202506
Drug: 50-mg udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg udenafil BID
Trial: 25936684
Drug: High-dose (71ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (71ml) GRE acquisitions
Trial: 25936684
Drug: Low-dose (24ml)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose (24ml) GRE scans
Trial: 25936684
Drug: High-dose (71ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (71ml) 3D-radial acquisitions
Trial: 25936684
Drug: Low-dose (24ml)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose (24ml) 3D-radial acquisitions
Trial: 24169052
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (BUD), 800 micrograms
Trial: 15822550
Drug: Aspiration combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration combined with methylprednisolone acetate injection plus wrist immobilization
Trial: 8598434
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diet and exercise
Trial: 8160980
Drug: Mannitol 0.5
RxNorm normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 0.5 g/kg in Group M
Trial: 20409444
Drug: Antidepressant discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant discontinuation
Trial: 27162089
Drug: Cabotegravir 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days
Trial: 27162089
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (single open-label dose)
Trial: 15136379
Drug: Pranlukast (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (225 mg bid)
Trial: 9494320
Drug: 1,800 cGy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,800 cGy whole brain radiation therapy (WBRT) plus intrathecal methotrexate (IT MTX)
Trial: 3326926
Drug: LHRH nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH nasal spray (400 micrograms three times a day for 28 days)
Trial: 31870562
Drug: Daily supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplement drink enriched with omega-3 fatty acids and vitamin D plus additional olive oil and olive oil-based spread
Trial: 29276990
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (BLT) plus care as usual
Trial: 22858745
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg INK
Trial: 22858745
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg INK
Trial: 22858745
Drug: 9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/kg INK
Trial: 18502003
Drug: DNA‐C priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA‐C priming (4 mg/ml) given intramuscularly at weeks 0 and 4 plus NYVAC‐C at weeks 20 and 24
Trial: 15316827
Drug: PSteE-milk (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSteE-milk (2.0 g plant sterols/d)
Trial: 15316827
Drug: PSteE-spread (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSteE-spread (4 g plant sterols/d)
Trial: 15316827
Drug: PSteE-yoghurt (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSteE-yoghurt (1.8 g plant sterols/d)
Trial: 15316827
Drug: PStaE-yoghurt (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PStaE-yoghurt (1.7 g plant stanols/d)
Trial: 15316827
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PSteE-milk and PSteE-spread
Trial: 10497456
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (25 micrograms with 12 mg of hyperbaric bupivacaine 0.75%)
Trial: 10497456
Drug: Preservative-free normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free normal saline (0.5 mL with 12 mg of hyperbaric bupivacaine 0.75%)
Trial: 24388737
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg
Trial: 19177029
Drug: Pharmacogenetics-guided dosing
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetics-guided dosing for warfarin therapy
Trial: 19177029
Drug: Traditional dosing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional dosing for warfarin therapy
Trial: 17640542
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment with combination of antiplatelet and anticoagulant therapy, early coronary angiography, revascularization, and anti-ischemic medical therapy.
Trial: 15274397
Drug: Methotrexate-modulated continuous
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate-modulated continuous infusion of 5-fluorouracil (ci5-FU/MTX)
Trial: 11762659
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (500 units, five tablets per day)
Trial: 11762659
Drug: Placebo (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (five placebo tablets per day)
Trial: 8220143
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mitozantrone and ifosfamide
Trial: 8220143
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent mitozantrone